Wie sind die Öffnungszeiten?

Montag 08:00 - 18:00 Dienstag 08:00 - 16:30 Mittwoch 08:00 - 18:00 Donnerstag 08:00 - 18:00 Freitag 08:00 - 16:30

CeGaT GmbH

Name: CeGaT GmbH
Address: Paul-Ehrlich-Straße 23, Tübingen, 72076, DE
Telephone: +4970715654455
Price range: $$
Rating: 5

CeGaT GmbH is a global provider of genetic analyses for various medical and research applications.
(2)

CeGaT GmbH, founded in Tübingen, Germany, is a world leader in gene analyses for a wide range of medical, research, and pharmaceutical applications. The company combines the latest sequencing technology with its many years of medical expertise – dedicated to identifying the genetic cause of disease and supporting patient care. For research and the pharmaceutical industry, CeGaT offers a broad port

folio of sequencing services and tumor analyses. CeGaT generates the data basis for clinical studies and medical innovations and drives science forward with own findings. The owner-managed company stands for independence, an extensive personal customer service, and the highest quality. To maintain the best results, all project steps are carried out in-house and under scientific supervision. CeGaT's laboratory is accredited according to CAP/CLIA and DIN EN ISO 15189, hence meeting high international standards.

31/08/2026

Genomics is the blueprint. Transcriptomics is the translator. Proteins are the actors.

Across oncology, immunology, neurology, infectious diseases, and metabolic research, the same challenge recurs: Genomic and transcriptomic data show what could happen and what is being expressed. But which proteins are present and active is determined at the protein level. That is where the functional state of the cell lives.

Is that layer visible in your data?

Our upcoming on-demand webinar on proteomics will cover the questions of where proteomics delivers the clearest added value, how Olink’s Proximity Extension Assay (PEA) technology works and what a project looks like in practice. Stay tuned.

25/08/2026

CeGaT’s Diagnostic Panel for Cardiac Diseases covers a broad range of genetic cardiovascular conditions, from cardiomyopathies and cardiac arrhythmias to congenital heart defects and familial hypercholesterolemias.

The panel has now been updated with 73 additional genes across several gene sets, while retaining the established panel structure. One of the most substantial changes concerns isolated and syndromal congenital heart defects, with the respective gene set now comprising 126 genes. The gene set for hereditary dyslipidemias has also been expanded from 12 to 18 genes and now covers a broader spectrum of conditions, including those associated with low HDL cholesterol and hypoalphalipoproteinemias.

12/08/2026

The right sequencing provider tells you what your sample can deliver for long-read WGS – before the run starts.

Sample quality is a key factor. Fragment size, purity, and concentration all shape what long-read sequencing can deliver. A good provider assesses these factors independently and is transparent about what they mean for your project.

Our Long-Read WGS Input Guide explains which parameters matter and what to look for in a provider before the run starts.
Download the guide here: https://cegat.com/research-pharma-solutions/hifi-wgs-guide/

05/08/2026

Standard genetic testing wasn’t enough – ExomeXtra® uncovered what others miss.

A 35-year-old patient presented with thrombotic microangiopathy (TMA) and kidney failure. Genetic testing with ExomeXtra® found no genetic variant but identified something else: Parvovirus B19, a rare trigger of TMA. This pivotal finding changed the course of treatment.

CeGaT’s ExomeXtra® enhances exome diagnostics with the screening of ongoing infections. Initially developed for prenatal diagnostics, this feature of ExomeXtra® now proves its value beyond that context by directly influencing clinical decision-making - even in adult patients. It delivers answers in complex cases where conventional exome diagnostics fall short.

31/07/2026

The American College of Medical Genetics and Genomics (ACMG) is now encouraging laboratories to adopt VUS (variants of unknown significance) subclasses in genetic reporting - bringing attention to variants most likely to explain a patient's phenotype, while de-emphasising those unlikely to be causal.

At CeGaT, this has been our standard for years.

We report VUS using the ACGS VUS Temperature Scale:
• the most likely relevant variants are on page one,
• for the sake of clarity and clinical utility, cool, cold, and ice-cold VUS are not reported.

Our reports help clinicians focus on what matters, instead of working through an unstructured list of uncertainty.

29/07/2026

A variant classified as a VUS today may be pathogenic tomorrow. Genetic testing only delivers answers if it keeps pace with the science. In our new series, CeGalotl asks our experts how CeGaT makes sure it does — swipe to find out.

A current example: CeGaT’s Diagnostic Panel for Liver Diseases. We're adding 18 genes to reflect the latest findings on hereditary liver disorders.

27/07/2026

Summer party at CeGaT!
A relaxed evening in Tübingen with colleagues from CeGaT, cecava GmbH, cenata, Zentrum für Humangenetik Tübingen, and MVZ Tübingen - good conversations, food and drinks, and time together beyond the daily work.

And our CeGalotl joined the party for the very first time - having the time of their life.

Thanks to everyone who made it such a great evening!

23/07/2026

For research where no reference genome exists, a de novo assembly establishes one from scratch. And even where a reference exists, rebuilding the genome de novo avoids reference bias – uncovering structural variants and regions that have no place in the standard reference.

With HiFi reads, larger fragments span more of the genome in a single read making the assembly more straightforward and the result more contiguous.

CeGaT now offers HiFi WGS De Novo for bacterial genomes.

21/07/2026

CancerPrecision®, CancerFusionRx®, and Our Diagnostic Panel for Hereditary Tumor Diseases Just Got an Upgrade!

The latest update sharpens diagnostic precision across our tumor panels and gives you more targeted options when testing for hereditary cancer syndromes.

What's new?

Diagnostic panel for hereditary tumor diseases:
• The former panel “Other Familial Tumor Diseases“ has been split into distinct, phenotype-specific gene sets – Cowden syndrome, Li-Fraumeni syndrome, neurofibromatosis/schwannomatosis, and tuberous sclerosis – for more targeted ordering instead of one broad panel.
• New CAN-all add-on: extend the analysis to the full panel for hereditary tumor diseases – covering additional differential diagnoses as well as secondary findings that indicate an increased risk for other tumor diseases in your patient (ACMG Class 4 and 5 variants)
• Pediatric solid tumor gene set expanded in line with the current S1 guideline on medulloblastoma

CancerPrecision® and CancerFusionRx®:
• Expanded gene and fusion coverage enables a more precise molecular profile of the tumor (e.g., ELOC for renal cell carcinoma and CREM fusions in Ewing sarcoma) – supporting more targeted therapy decisions and precise tumor classification .

This update ensures your diagnostics are always based on the latest scientific findings.
Explore our comprehensive tumor diagnostics portfolio:

17/07/2026

Building a national cancer detection program takes more than an accurate test. It takes a partner who understands the infrastructure behind it.

This week, we hosted a delegation from Libya's National Cancer Control Authority (NCCA) at CeGaT in Tübingen. Their mandate: establishing systematic, earlier cancer detection at a national level.

The visit focused on our tumor diagnostics portfolio - including CancerPrecision and CancerMRD - and on what it takes to scale diagnostic capability into a program that reaches an entire population.

We look forward to seeing where this partnership with the NCCA leads.

Adresse

Paul-Ehrlich-Straße 23
Tübingen
72076

Öffnungszeiten

Montag	08:00 - 18:00
Dienstag	08:00 - 16:30
Mittwoch	08:00 - 18:00
Donnerstag	08:00 - 18:00
Freitag	08:00 - 16:30

Telefon

+4970715654455

Webseite

https://www.cegat.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von CeGaT GmbH erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.